|Trade names||Atravet, Acezine 2|
|AHFS/Drugs.com||International Drug Names|
|IV, IM, SQ, oral|
|Bioavailability||6.6 L/kg, high volume of distribution|
|Elimination half-life||3 hours in horses, 15.9 hours in canines|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||326.456 g·mol−1|
|3D model (JSmol)|
Acepromazine, acetopromazine, or acetylpromazine (commonly known as ACP, Ace, or by the trade names Atravet or Acezine 2, number depending on mg/ml dose) is a phenothiazine derivative antipsychotic drug. It was used in humans during the 1950s as an antipsychotic, but is now almost exclusively used on animals as a sedative and antiemetic. Its closely related analogue, chlorpromazine, is still used as an antipsychotic in humans. Acepromazine is used primarily as a chemical restraint in hyperactive or fractious animals.
The standard pharmaceutical preparation, acepromazine maleate, is used in veterinary medicine in dogs and cats. It is used widely in horses as a pre-anesthetic sedative and has been shown to reduce anesthesia related death. However, it should be used with caution (but is not absolutely contraindicated) in stallions due to the risk of paraphimosis and persistent priapism. Its potential for cardiac effects can be profound, namely hypotension due to peripheral vasodilation, so it should be avoided or used with caution in geriatric or debilitated animals.
The clinical pharmacology of acepromazine is similar to that of other phenothiazine derived anti-psychotic agents. The primary behavioral effects are attributed to its potent antagonism of post-synaptic D2 receptors and, to a lesser degree, the other D2-like receptors. Additional effects are related to its appreciable antagonistic effects on various other receptors, including the α1 receptors, H1 receptors, and mACh receptors. It is metabolized by the liver, oxidized to produce its primary metabolite, hydroxyethylpromazine sulfoxide, which is then excreted in the urine.: 115 Its action at the chemoreceptor trigger zone (in the area postrema) and the solitary nucleus (in the medulla oblongata) allow it to have an antiemetic effect.
Canine and feline
The most common uses of acepromazine in animals are as an oral sedative before stressful events (such as thunderstorms), an injectable tranquilizer for particularly aggressive or fractious animals, and in combination with analgesics and other sedatives. It is also labeled for use in preventing motion sickness. Its effects as a CNS depressant means that less opiates are required to reach the same amount of sedation, and it prevents the arrhythmia and vomiting that many opiates induce. Its use as an oral sedative is somewhat controversial; acepromazine can increase sensitivity to noise and cause exaggerated startle reflexes. The dysphoric effect of phenothiazines and this increase in sensitivity can make some aggressive dogs and fractious cats more so.: 116, 130 
Adverse effects in cats
While acepromazine is also used in cats, its absorption is erratic and can differ wildly from one cat to the next. It also generally induces less sedation than in dogs. It also causes spontaneous motor activity (in both cats and dogs, but more often in cats) by blocking dopamine receptors in the striatum and substantia nigra.
Adverse effects in dogs
Literature from the 1950s raised concerns about phenothiazine-induced seizures in human patients. For this reason, caution has typically been advised when contemplating acepromazine use in epileptic canine patients, as it was widely believed to lower the seizures threshold. More current studies, however, have failed to show a positive association between use of acepromazine and seizure activity: 116  and show a possible role for acepromazine in seizure control: in a retrospective study at University of Tennessee, acepromazine was administered for tranquilization to 36 dogs with a prior history of seizures and to decrease seizure activity in 11 dogs. No seizures were seen within 16 hours of acepromazine administration in the 36 dogs that received the drug, and the seizures abated for 1.5 to 8 hours (n=6) or did not recur (n=2) in eight of 10 dogs that were actively seizing. Excitement-induced seizures were reduced for 2 months in one dog. A second retrospective study also concluded that administration of acepromazine to dogs with prior or acute seizure history did not potentiate seizures, and there was some trend toward seizure reduction. The original seizure cautions reported in the 1950s were in human patients on relatively high doses of the antipsychotic chlorpromazine while the doses of acepromazine used in the two published veterinary studies cited above are much lower.
In some boxers, acepromazine can cause vasovagal syncope (due to a decreased stimulation of the sympathetic nervous system) and hypotension (due to vasodilation), leading to collapse. This may occur only in certain families of boxers, but the unknown risk to an individual dog means that acepromazine should be used at reduced doses, or not at all, in this breed. Individual dogs of any breed can have a profound reaction characterized by hypotension, especially if there is an underlying heart problem.
Dogs with a mutation in the ABCB1 (MDR1) gene
P-glycoprotein (P-gp), also known as multidrug resistant protein 1 (MDR1), is a protein found in cell membranes which is important in the metabolism and excretion of some drugs,: 41–58 such as acepromazine and ivermectin. This protein is encoded by the ABCB1 gene (previously known as the MDR1 gene). A mutation in ABCB1 prevents P-gp from being correctly produced, so that dogs with this mutation have an increased sensitivity to drugs (such as acepromazine) which are substrates of P-gp. Dogs which are heterozygous (that is, which have one functioning ABCB1 gene, and one non-functioning gene) are less sensitive to acepromazine than dogs which are homozygous (that is, which have two copies of the mutant gene). 75% of Collies carry the mutated ABCB1 gene, as do 50% of Australian Shepherds. Other affected breeds include: Border Collie, English Shepherd, German Shepherd, Old English Sheepdog, and Sighthounds, shelties, long haired greyhound.
Tests for this mutation are available.
In equine surgery, premedication with acepromazine has been shown to reduce the perianaesthetic mortality rate, possibly due to its actions as a sedative and anxiolytic. It is less effective as a sedative if the horse is already excited.
Additionally, acepromazine is used as a vasodilator in the treatment of laminitis, where an oral dose equivalent to "mild sedation" is commonly used, although the dose used is highly dependent on the treating veterinarian. While it is shown to elicit vasodilation in the distal limb, evidence showing its efficacy at increasing perfusion in the laminae is lacking. It is also sometimes used to treat a horse experiencing equine exertional rhabdomyolysis.
In the UK, acepromazine is not authorized for use in horses intended for human consumption.
Acepromazine also lowers blood pressure, and should therefore be used with caution in horses that are experiencing anemia, dehydration, shock, or colic. It should not be used in horses dewormed with piperazine.
- "Acepromazine Maleate Injection for Animal Use". Drugs.com. Retrieved 2017-06-11.
- "Acepromazine: Pet Anxiety Medication for Dogs & Cats". 1800PetMeds. Retrieved 2017-06-11.
- Collard JF, Maggs R (June 1958). "Clinical Trial of Acepromazine Maleate in Chronic Schizophrenia". British Medical Journal. 1 (5085): 1452–4. doi:10.1136/bmj.1.5085.1452. PMC 2029326. PMID 13536530.
- Dugdale, AH; Taylor, PM (May 2016). "Equine anaesthesia-associated mortality: where are we now?". Veterinary Anaesthesia and Analgesia. 43 (3): 242–55. doi:10.1111/vaa.12372. PMID 26970940.
- Plumb, Donald C. (2011). Plumb's Veterinary Drug Handbook, 7th ed. Ames, Iowa: Wiley-Blackwell. pp. 4–5. ISBN 978-0-4709-5965-7.
- Forney, Barbara. "Acepromazine Maleate for Veterinary Use". Wedgewood pharmacy. Retrieved 2017-06-10.
- Choudhary, Gargi. "Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer" (PDF). Thermo Electron Corporation.
- Maddison, Jill E.; Page, Stephen W.; Church, David, eds. (2008). Small Animal Clinical Pharmacology (2 ed.). Edinburgh; New York: Saunders/Elsevier. ISBN 9780702028588.
- Valverde, A; Cantwell, S; Hernández, J; Brotherson, C (April 2003). "Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs". Veterinary Anaesthesia and Analgesia. 30 (2): 99. doi:10.1046/j.1467-2995.2003.01331.x. ISSN 1467-2987. PMID 28404438.
- Kolahian, Saeed (2014). "Efficacy of Different Antiemetics with Different Mechanism of Action on Xylazine Induced Emesis in Cats" (PDF). Iranian Journal of Veterinary Surgery. 9 (1): 10.
- Park E. Motion sickness. In: General Medical Officer (GMO) Manual: Clinical Section. Wilmette, IL: Brookside Press; 1999.
- Khuly, Patty (2009-10-22). "Acepromazine: Why I'm not a big fan when it comes to sedation via 'ace'". PetMD. Retrieved 2017-06-12.
- Marroum, Patrick John (1990). Pharmacokinetic studies of acepromazine in the cat and the horse, studies in lipophilicity, red blood cell partitioning and protein binding (PhD). University of Florida.
- Wingfield, Wayne; Raffe, Marc (2002-09-29). The Veterinary ICU Book. Teton NewMedia. p. 81. ISBN 9781893441132.
- Riviere, JE; Papich, MG, eds. (2009). Veterinary pharmacology and therapeutics (9th ed.). Ames, Iowa: Wiley-Blackwell. pp. 340, 561. ISBN 978-0-8138-2061-3.
- Brooks, Wendy. "Acepromazine (PromAce)". The Pet Pharmacy. Retrieved 2017-06-11.
- Tobias, Karen M; Marioni-Henry, Katia; Wagner, Rebecca (July 1, 2006). "A Retrospective Study on the Use of Acepromazine Maleate in Dogs With Seizures". Journal of the American Animal Hospital Association. 42 (4): 283–289. doi:10.5326/0420283.
- McConnell J, Kirby R, Rudloff E (2007). "Administration of acepromazine maleate to 31 dogs with a history of seizures". Journal of Veterinary Emergency and Critical Care. 17 (3): 262–7. doi:10.1111/j.1476-4431.2007.00231.x.
- Wieder, M. E.; Gray, B. P.; Brown, P. R.; Hudson, S.; Pearce, C. M.; Paine, S. W.; Hillyer, L. (2012). "Identification of Acepromazine and Its Metabolites in Horse Plasma and Urine by LC–MS/MS and Accurate Mass Measurement". Chromatographia. 75 (11–12): 635–643. doi:10.1007/s10337-012-2234-4. ISSN 0009-5893.
- Ettinger, SJ; Feldman, EC, eds. (2010). Textbook of veterinary internal medicine: Diseases of the dog and the cat (7th ed.). St. Louis, Mo.: Elsevier Saunders. ISBN 978-1-4160-6593-7.
- Mealey, KL (September 2013). "Adverse drug reactions in veterinary patients associated with drug transporters". Veterinary Clinics of North America: Small Animal Practice. 43 (5): 1067–78. doi:10.1016/j.cvsm.2013.04.004. PMID 23890239.
- "Multidrug Sensitivity in Dogs". Washington State University.
- Thayer, Asia (2009). "HA Special Care Drug Chart" (PDF). Retrieved 2017-06-19.
- National Office of Animal Health (2004). NOAH Compendium of Data Sheets for Animal Medicines 2005:38. Enfield: National Office of Animal Health. ISBN 9780954803704.